Research demonstrates tumor progression in cancer-associated depression, highlighting new pharmacological interventions.
We emphasize the rationale and importance of developing pharmacological interventions to inhibit tumor progression and enhance the efficacy of conventional therapies and immunotherapies in patients with cancer-associated depression. Moreover, we discuss emerging pharmacological strategies with the potential to prevent stress-related cancer progression.
No takes yet. Share an insight, caveat, or question.
Ge et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: